Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Catequentinib hydrochloride by Advenchen Laboratories for Metastatic Pancreatic Cancer: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Metastatic Pancreatic Cancer. According to...
Catequentinib hydrochloride by Advenchen Laboratories for Oral Cancer: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Oral Cancer. According to GlobalData,...
Catequentinib hydrochloride by Advenchen Laboratories for Non-Small Cell Lung Cancer: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Non-Small Cell Lung Cancer. According...
Catequentinib hydrochloride by Advenchen Laboratories for Solid Tumor: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Solid Tumor. According to GlobalData,...
Catequentinib hydrochloride by Advenchen Laboratories for Small-Cell Lung Cancer: Likelihood of Approval
Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Small-Cell Lung Cancer. According to...